Cargando…
Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993431/ https://www.ncbi.nlm.nih.gov/pubmed/32005287 http://dx.doi.org/10.1186/s13058-020-1254-5 |
| _version_ | 1783493032065105920 |
|---|---|
| author | Pancholi, Sunil Leal, Mariana Ferreira Ribas, Ricardo Simigdala, Nikiana Schuster, Eugene Chateau-Joubert, Sophie Zabaglo, Lila Hills, Margaret Dodson, Andrew Gao, Qiong Johnston, Stephen R. Dowsett, Mitch Cosulich, Sabina C. Marangoni, Elisabetta Martin, Lesley-Ann |
| author_facet | Pancholi, Sunil Leal, Mariana Ferreira Ribas, Ricardo Simigdala, Nikiana Schuster, Eugene Chateau-Joubert, Sophie Zabaglo, Lila Hills, Margaret Dodson, Andrew Gao, Qiong Johnston, Stephen R. Dowsett, Mitch Cosulich, Sabina C. Marangoni, Elisabetta Martin, Lesley-Ann |
| author_sort | Pancholi, Sunil |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6993431 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-69934312020-02-04 Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer Pancholi, Sunil Leal, Mariana Ferreira Ribas, Ricardo Simigdala, Nikiana Schuster, Eugene Chateau-Joubert, Sophie Zabaglo, Lila Hills, Margaret Dodson, Andrew Gao, Qiong Johnston, Stephen R. Dowsett, Mitch Cosulich, Sabina C. Marangoni, Elisabetta Martin, Lesley-Ann Breast Cancer Res Correction BioMed Central 2020-01-31 2020 /pmc/articles/PMC6993431/ /pubmed/32005287 http://dx.doi.org/10.1186/s13058-020-1254-5 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Correction Pancholi, Sunil Leal, Mariana Ferreira Ribas, Ricardo Simigdala, Nikiana Schuster, Eugene Chateau-Joubert, Sophie Zabaglo, Lila Hills, Margaret Dodson, Andrew Gao, Qiong Johnston, Stephen R. Dowsett, Mitch Cosulich, Sabina C. Marangoni, Elisabetta Martin, Lesley-Ann Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer |
| title | Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer |
| title_full | Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer |
| title_fullStr | Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer |
| title_full_unstemmed | Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer |
| title_short | Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer |
| title_sort | correction to: combination of mtorc1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993431/ https://www.ncbi.nlm.nih.gov/pubmed/32005287 http://dx.doi.org/10.1186/s13058-020-1254-5 |
| work_keys_str_mv | AT pancholisunil correctiontocombinationofmtorc12inhibitorvistusertibplusfulvestrantinvitroandinvivotargetsoestrogenreceptorpositiveendocrineresistantbreastcancer AT lealmarianaferreira correctiontocombinationofmtorc12inhibitorvistusertibplusfulvestrantinvitroandinvivotargetsoestrogenreceptorpositiveendocrineresistantbreastcancer AT ribasricardo correctiontocombinationofmtorc12inhibitorvistusertibplusfulvestrantinvitroandinvivotargetsoestrogenreceptorpositiveendocrineresistantbreastcancer AT simigdalanikiana correctiontocombinationofmtorc12inhibitorvistusertibplusfulvestrantinvitroandinvivotargetsoestrogenreceptorpositiveendocrineresistantbreastcancer AT schustereugene correctiontocombinationofmtorc12inhibitorvistusertibplusfulvestrantinvitroandinvivotargetsoestrogenreceptorpositiveendocrineresistantbreastcancer AT chateaujoubertsophie correctiontocombinationofmtorc12inhibitorvistusertibplusfulvestrantinvitroandinvivotargetsoestrogenreceptorpositiveendocrineresistantbreastcancer AT zabaglolila correctiontocombinationofmtorc12inhibitorvistusertibplusfulvestrantinvitroandinvivotargetsoestrogenreceptorpositiveendocrineresistantbreastcancer AT hillsmargaret correctiontocombinationofmtorc12inhibitorvistusertibplusfulvestrantinvitroandinvivotargetsoestrogenreceptorpositiveendocrineresistantbreastcancer AT dodsonandrew correctiontocombinationofmtorc12inhibitorvistusertibplusfulvestrantinvitroandinvivotargetsoestrogenreceptorpositiveendocrineresistantbreastcancer AT gaoqiong correctiontocombinationofmtorc12inhibitorvistusertibplusfulvestrantinvitroandinvivotargetsoestrogenreceptorpositiveendocrineresistantbreastcancer AT johnstonstephenr correctiontocombinationofmtorc12inhibitorvistusertibplusfulvestrantinvitroandinvivotargetsoestrogenreceptorpositiveendocrineresistantbreastcancer AT dowsettmitch correctiontocombinationofmtorc12inhibitorvistusertibplusfulvestrantinvitroandinvivotargetsoestrogenreceptorpositiveendocrineresistantbreastcancer AT cosulichsabinac correctiontocombinationofmtorc12inhibitorvistusertibplusfulvestrantinvitroandinvivotargetsoestrogenreceptorpositiveendocrineresistantbreastcancer AT marangonielisabetta correctiontocombinationofmtorc12inhibitorvistusertibplusfulvestrantinvitroandinvivotargetsoestrogenreceptorpositiveendocrineresistantbreastcancer AT martinlesleyann correctiontocombinationofmtorc12inhibitorvistusertibplusfulvestrantinvitroandinvivotargetsoestrogenreceptorpositiveendocrineresistantbreastcancer |